Project Grant R00HL157689
Award Date
8/12/24
Completion Date
7/31/27
Dollars Obligated
$500K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at the Texas Heart Institute (THI) to elucidate the role of senescent cardiac tissue-resident macrophages in heart failure progression. The $651,967 award, effective from August 1, 2025 to May 31, 2030, will support mechanistic studies to understand how macrophage senescence promotes cardiomyocyte dysfunction,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
This federal Project Grant award, with a total funding amount of $153,252, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support a 3-year research program focused on elucidating the molecular mechanisms and clinical significance of a specific macrophage population (SPP1+ macrophages) in peripheral arterial disease (PAD). The primary objectives are to determine if SPP1+ macrophages inhibit...
The National Heart Lung and Blood Institute (NHLBI) awarded a $111,626 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to investigate ways to target macrophage populations and attenuate pulmonary hypertension associated with sickle cell disease. The 2-year project aims to determine if modifying iron release from the ferroportin transporter can alter CD169+ macrophage and adaptive immune cell quantities, phenotypes, and oxidative status (Aim 1);...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of reduced hypusination of the translation factor EIF5A in the development of heart failure with preserved ejection fraction (HFpEF). The $126,387 award to The Johns Hopkins University, granted on June 15, 2025, aims to study how depressed EIF5A hypusination impairs the translation of ubiquitin precursors and...
This Project Grant award of $108,030, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine if neutrophils produced through emergency granulopoiesis, a reactive process that increases neutrophil production during immune challenges like myocardial infarction (MI), exhibit altered functions that contribute to the pathogenesis of heart failure after MI. The key objectives are 1) to assess...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $784,206 to investigate the role of the CSF-1/CSF-1R axis in myocardial infarction (MI) repair and remodeling. The award to Albert Einstein College of Medicine will fund research to: 1) examine the in vivo effects of macrophage-specific CSF-1R activation on cardiac repair and remodeling after MI; 2) investigate the role of fibroblast-derived CSF-1 in...